Long-term protection of the rat nigrostriatal dopaminergic system by glial cell line-derived neurotrophic factor against 6-hydroxydopamine in vivo - PubMed (original) (raw)

Long-term protection of the rat nigrostriatal dopaminergic system by glial cell line-derived neurotrophic factor against 6-hydroxydopamine in vivo

A M Sullivan et al. Eur J Neurosci. 1998 Jan.

Abstract

Glial cell-line-derived neurotrophic factor (GDNF) has been shown to enhance the survival of dopaminergic neurones both in vitro and in vivo, and to protect the rodent dopaminergic system from neurotoxic damage. However, most previous studies have only examined the short-term protective effects of GDNF. We have investigated the long-term effects of GDNF on a 6-hydroxydopamine (6-OHDA)-induced lesion of the rat medial forebrain bundle (MFB), which results in complete and irreversible destruction of the nigrostriatal pathway, and is a robust model of Parkinson's disease. GDNF was administered ipsilaterally above the substantia nigra and into the lateral ventricle immediately before a unilateral 6-OHDA injection into the MFB. The effects of GDNF were examined in vivo by behavioural testing and positron emission tomography (PET) at weekly intervals, for 12 weeks. GDNF prevented the development of amphetamine-induced rotations at all time-points. PET studies, using [11C]-RTI-121 as a tracer for the dopamine transporter, indicated that GDNF prevented 6-OHDA-induced reduction of dopamine reuptake sites in the ipsilateral striatum. Post-mortem neurochemical analysis at 13 weeks after surgery found that GDNF significantly inhibited 6-OHDA-induced loss of dopamine, 3,4-dihydroxyphenylacetic acid and homovanillic acid in the ipsilateral striatum. Immunocytochemistry showed that GDNF reduced 6-OHDA-induced loss of tyrosine hydroxylase-positive neurones in both the substantia nigra pars compacta and ventral tegmental area. We have shown that a single treatment with GDNF can confer long-term protective effects against a 6-OHDA lesion, which suggests that this factor may be useful for the treatment of Parkinson's disease.

PubMed Disclaimer

Cited by

Controlled release of glial cell line-derived neurotrophic factor from poly(ε-caprolactone) microspheres.
Agbay A, Mohtaram NK, Willerth SM. Agbay A, et al. Drug Deliv Transl Res. 2014 Apr;4(2):159-70. doi: 10.1007/s13346-013-0189-0. Drug Deliv Transl Res. 2014. PMID: 25786730
Neuroprotective Surgical Strategies in Parkinson's Disease: Role of Preclinical Data.
Torres N, Molet J, Moro C, Mitrofanis J, Benabid AL. Torres N, et al. Int J Mol Sci. 2017 Oct 20;18(10):2190. doi: 10.3390/ijms18102190. Int J Mol Sci. 2017. PMID: 29053638 Free PMC article. Review.
Treatment of Parkinson's disease with biologics that penetrate the blood-brain barrier via receptor-mediated transport.
Pardridge WM. Pardridge WM. Front Aging Neurosci. 2023 Nov 13;15:1276376. doi: 10.3389/fnagi.2023.1276376. eCollection 2023. Front Aging Neurosci. 2023. PMID: 38035276 Free PMC article. Review.
Growth/differentiation factor-15/macrophage inhibitory cytokine-1 is a novel trophic factor for midbrain dopaminergic neurons in vivo.
Strelau J, Sullivan A, Böttner M, Lingor P, Falkenstein E, Suter-Crazzolara C, Galter D, Jaszai J, Krieglstein K, Unsicker K. Strelau J, et al. J Neurosci. 2000 Dec 1;20(23):8597-603. doi: 10.1523/JNEUROSCI.20-23-08597.2000. J Neurosci. 2000. PMID: 11102463 Free PMC article.
Quantitative Rodent Brain Receptor Imaging.
Herfert K, Mannheim JG, Kuebler L, Marciano S, Amend M, Parl C, Napieczynska H, Maier FM, Vega SC, Pichler BJ. Herfert K, et al. Mol Imaging Biol. 2020 Apr;22(2):223-244. doi: 10.1007/s11307-019-01368-9. Mol Imaging Biol. 2020. PMID: 31168682 Review.

Long-term protection of the rat nigrostriatal dopaminergic system by glial cell line-derived neurotrophic factor against 6-hydroxydopamine in vivo - PubMed (original) (raw)